Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone. Issue 6 (19th March 2021) - Korde, Neha; Mastey, Donna; Tavitian, Elizabet; Mailankody, Sham; Lesokhin, Alexander; Hassoun, Hani; Smith, Eric L.; Lendvai, Nikoletta; Hultcrantz, Malin; Shah, Urvi; Tan, Carlyn; Lu, Sydney; et al.